Biognosys Portfolio – Transformative Insights from Discovery to Clinic
This comprehensive brochure provides an overview of our services, software, and kits offering.
This comprehensive brochure provides an overview of our services, software, and kits offering.
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
The brochure provides an overview of the key features and benefits of our next-generation TrueSignature platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.
Learn more about Biognosys’ proprietary TrueTarget platform in our latest brochure. This resource elaborates on how TrueTarget identifies the most promising and actionable drug targets to support your research.
Our latest white paper highlights our advanced plasma proteomics capabilities, driven by the P2 Enrichment System. The study demonstrates how TrueDiscovery Plasma Biomarker Discovery services achieve an optimal balance between depth, throughput, and sensitivity, enabling their application in informed clinical decision-making.
Discover how Biognosys’ advanced immunopeptidome profiling services and tailored bioinformatics enable precise identification and quantification of MHC-presented peptides in human and preclinical species.
Explore how our mass spectrometry-based TrueDiscovery tissue proteomics platform provides deep, unbiased, and label-free protein profiling with peptide-level resolution, capturing the full complexity of the proteome.
Biognosys’ advanced immunopeptidome profiling services and tailored bioinformatics enable precise identification and quantification of MHC-presented peptides in human and pre-clinical species using minimal sample input. With extensive experience in TCR-T therapies, cancer vaccines, and immunomodulatory treatments, Biognosys is your trusted partner in driving innovation in precision therapies.
Discover how our quantitative metabolomics services deliver robust, reproducible measurement of 1,500+ metabolites and lipids across 100+ pathways, enabling direct insight into disease mechanisms, patient stratification, and therapeutic response.
Biognosys’ MS-based targeted proteomics platform, TrueSignature, enables absolute, antibody-independent quantification at the peptide level. Download the flyer to learn more.
Explore how our TrueSignature targeted proteomics platform offers a robust CRO service for precise protein quantification across diverse biological matrices and species.
Download our latest application note to discover how SISCAPA is powering next-generation targeted proteomics for hard-to-measure proteins.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 244 50 00
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
